Tris Pharma Settled Claims Over ADHD Drug Marketing
The company agreed to pay $7.5 million to resolve allegations that it misrepresented the efficacy of Dyanavel XR.
Updated on Oct. 1, 2026 in Healthcare
Live Poll
Should pharmaceutical companies face financial penalties for making misleading drug marketing claims?
Tris Pharma has reached a $7.5 million settlement to resolve claims brought by the state of Texas and a whistleblower. The lawsuit alleged the company misled Medicaid providers regarding the effectiveness of its ADHD medication, Dyanavel XR.
Why it matters
The settlement addresses allegations that the company improperly influenced medical providers by exaggerating the performance of a drug marketed for children. This resolution concludes a legal challenge centered on the integrity of pharmaceutical marketing practices.
Tris Pharma agreed to pay $7.5 million to settle claims brought by the state of Texas and a whistleblower. The case represents a significant resolution regarding allegations of deceptive pharmaceutical marketing.
The players
Tris Pharma
This is a pharmaceutical company that manufactures and markets medications, including treatments for attention-deficit/hyperactivity disorder.
Ketan Mehta
He is the Chief Executive Officer of Tris Pharma and was named alongside the company in the legal dispute.
The details
Texas alleged that the company instructed sales representatives to tell doctors that Dyanavel XR worked faster than competing ADHD treatments. While Tris Pharma and CEO Ketan Mehta agreed to the payout to resolve the claims, both parties continue to deny any wrongdoing.
Timeline
The Texas Attorney General announced the settlement on September 24, 2026.
Market Landscape
The settlement follows a long-standing pattern of state and federal authorities utilizing the False Claims Act to penalize companies for deceptive marketing practices involving Medicaid. This resolution positions the state of Texas as an active enforcer against pharmaceutical companies that allegedly prioritize marketing claims over clinical accuracy.
The settlement does not immediately alter the availability of Dyanavel XR for patients or change existing prescription protocols. However, it highlights the ongoing oversight of pharmaceutical marketing tactics used by providers when managing ADHD treatments for children.
The takeaway
Pharmaceutical companies face strict scrutiny when promoting drug performance to medical providers through state-funded programs. Families should consult with their healthcare providers to verify clinical data regarding medication efficacy.
Further reading
Learn more about local regulatory actions by visiting our Healthcare section.
Live Poll
Should pharmaceutical companies face financial penalties for making misleading drug marketing claims?
